Polymorphisms in Nucleotide Excision Repair Genes, Arsenic Exposure, and Non-melanoma Skin Cancer in New Hampshire

DSpace/Manakin Repository

Polymorphisms in Nucleotide Excision Repair Genes, Arsenic Exposure, and Non-melanoma Skin Cancer in New Hampshire

Citable link to this page

 

 
Title: Polymorphisms in Nucleotide Excision Repair Genes, Arsenic Exposure, and Non-melanoma Skin Cancer in New Hampshire
Author: Karagas, Margaret R.; Byler, Steven H.; Morris, Steve; Nelson, Heather H.; Applebaum, Katie Lyn; Hunter, David J.; Catalano, Paul J.

Note: Order does not necessarily reflect citation order of authors.

Citation: Applebaum, Katie M., Margaret R. Karagas, David J. Hunter, Paul J. Catalano, Steven H. Byler, Steve Morris, and Heather H. Nelson. 2007. Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environmental Health Perspectives 115(8): 1231-1236.
Full Text & Related Files:
Abstract: Background: Arsenic exposure may alter the efficiency of DNA repair. UV damage is specifically repaired by nucleotide excision repair (NER), and common genetic variants in NER may increase risk for non-melanoma skin cancer (NMSC). Objective: We tested whether polymorphisms in the NER genes XPA (A23G) and XPD (Asp312Asn and Lys751Gln) modify the association between arsenic and NMSC. Methods: Incident cases of basal and squamous cell carcinoma (BCC and SCC, respectively) were identified through a network of dermatologists and pathology laboratories across New Hampshire. Population-based controls were frequency matched to cases on age and sex. Arsenic exposure was assessed in toenail clippings. The analysis included 880 cases of BCC, 666 cases of SCC, and 780 controls. Results: There was an increased BCC risk associated with high arsenic exposure among those homozygous variant for XPA [odds ratio (OR) = 1.8; 95% confidence interval (CI), 0.9–3.7]. For XPD, having variation at both loci (312Asn and 751Gln) occurred less frequently among BCC and SCC cases compared with controls (OR = 0.8; 95% CI, 0.6–1.0) for both case groups. In the stratum of subjects who have variant for both XPD polymorphisms, there was a 2-fold increased risk of SCC associated with elevated arsenic (OR = 2.2; 95% CI, 1.0–5.0). The test for interaction between XPD and arsenic in SCC was of borderline significance (p < 0.07, 3 degrees of freedom). Conclusions: Our findings indicate a reduced NMSC risk in relation to XPD Asp312Asn and Lys751Gln variants. Further, these data support the hypothesis that NER polymorphisms may modify the association between NMSC and arsenic.
Published Version: doi://10.1289/ehp.10096
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1940098/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5978734
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters